ArticleRSC advances2026
A ternary nanocomplex for hepatocyte-targeted gene delivery and treatment of metabolic dysfunction-associated steatotic liver disease.
Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The liver, with its unique physiology and powerful metabolic activity, represents an ideal 'protein factory' for gene therapy. Yet efficient, cell-specific transfection of hepatocytes remains a significant challenge. To address this, we engineered a novel ternary nanocomplex through a modular design. A stable binary core was first formed by electrostatically condensing plasmid DNA (pDNA) with a fluorinated ROS-cleavable (TK) polyethylenimine (FRP), enhancing cellular uptake and facilitating endosomal escape. This core was subsequently coated with a surface layer of galactose-modified hyaluronic acid-polyethylene glycol (GPH), enabling dual-receptor-mediated hepatocyte targeting. Galactose (Gal) engages the asialoglycoprotein receptor (ASGPR) and hyaluronic acid (HA) interacts with CD44 on hepatocytes, while the PEG corona improves complex stability.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.